Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes.

Abstract

People with diabetes are at risk of chronic complications and novel biomarkers, such as Advanced glycation end-products (AGEs) may help stratify this risk. We assessed whether plasma low-molecular weight AGEs, also known as LMW-fluorophores (LMW-F), are associated with risk factors, predict complications, and are altered by fenofibrate in adults with type 2 diabetes. Plasma LMW-F were quantified at baseline, after six weeks fenofibrate, and one year post-randomisation to fenofibrate or placebo. LMW-F associations with existing and new composite vascular complications were determined, and effects of fenofibrate assessed. LMW-F correlated positively with age, glycated haemoglobin (HbA1c), pulse pressure, kidney dysfunction and inflammation; and negatively with urate, body mass index, oxidative stress and leptin, albeit weakly (r = 0.04-0.16, all p < 0.01). Independent determinants of LMW-F included smoking, diastolic blood pressure, prior cardiovascular disease or microvascular complications, Caucasian ethnicity, kidney function, HbA1c and diabetes duration (all p ≤ 0.01). Baseline LMW-F tertiles correlated with on-trial macrovascular and microvascular complications (trend p < 0.001) on univariate analyses only. Six weeks of fenofibrate increased LMW-F levels by 21% (p < 0.001). In conclusion, LMW-F levels correlate with many risk factors and chronic diabetes complications, and are increased with fenofibrate. LMW-F tertiles predict complications, but not independently of traditional risk factors.

• Authors: Andrzej S Januszewski, David Chen, Russell S Scott, Rachel L O'Connell, Nanda R Aryal, David R Sullivan, Gerald F Watts, Marja-Riitta Taskinen, Philip J Barter, James D Best, R John Simes, Anthony C Keech, Alicia J Jenkins
• Journal: Scientific reports (Sci Rep) Vol. 11 Issue 1 Pg. 18708 (09 21 2021) ISSN: 2045-2322 [Electronic] England
• PMID: 34548531 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021. The Author(s).

Chemical References

• Fluorescent Dyes
• Hypolipidemic Agents
• Fenofibrate

Topics

• Adult
• Aged
• Diabetes Mellitus, Type 2 (drug therapy)
• Female
• Fenofibrate (therapeutic use)
• Fluorescent Dyes (chemistry)
• Humans
• Hypolipidemic Agents (therapeutic use)
• Male
• Middle Aged
• Molecular Weight